Is there a Bearish outlook for Halozyme Therapeutics, Inc. (NASDAQ:HALO) this week?

November 10, 2018 - By Hugh Holland

Halozyme Therapeutics, Inc. (NASDAQ:HALO) LogoInvestors sentiment decreased to 0.95 in 2018 Q2. Its down 0.56, from 1.51 in 2018Q1. It worsened, as 25 investors sold Halozyme Therapeutics, Inc. shares while 59 reduced holdings. 25 funds opened positions while 55 raised stakes. 118.72 million shares or 0.69% less from 119.54 million shares in 2018Q1 were reported.
Mackay Shields Lc holds 0.01% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 43,663 shares. The New Jersey-based Landscape Mgmt Ltd Limited Liability Company has invested 0.02% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Daiwa Group accumulated 787 shares. Renaissance Techs Limited Com has invested 0.02% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Adams Diversified Equity Fund owns 29,900 shares. Kennedy Cap Mngmt has invested 0.19% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Amalgamated Bank & Trust has 19,053 shares for 0.01% of their portfolio. Dekabank Deutsche Girozentrale reported 0% stake. Fisher Asset Llc accumulated 453,652 shares or 0.01% of the stock. Hbk Investments L P has 28,700 shares for 0% of their portfolio. Smith Asset Management Grp Lp stated it has 0.01% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Snyder L P has invested 1.9% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Gsa Ptnrs Ltd Liability Partnership reported 0.07% stake. 10,685 were accumulated by Ameritas Invest Partners. Dixon Hubard Feinour & Brown Va has 0.08% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 16,702 shares.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

Among 4 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Halozyme Therapeutics had 4 analyst reports since May 11, 2018 according to SRatingsIntel. As per Wednesday, August 8, the company rating was maintained by BMO Capital Markets. The rating was maintained by Canaccord Genuity on Monday, May 14 with “Buy”. The rating was downgraded by Barclays Capital on Friday, May 11 to “Underweight”. Below is a list of Halozyme Therapeutics, Inc. (NASDAQ:HALO) latest ratings and price target changes.

23/08/2018 Broker: Cantor Fitzgerald Rating: Overweight New Target: $27 Initiates Coverage On
08/08/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $19 New Target: $21 Maintain
14/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0000 Maintain
11/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $19 Downgrade

The stock decreased 2.22% or $0.36 during the last trading session, reaching $15.89. About 781,513 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 32.24% since November 10, 2017 and is uptrending. It has outperformed by 16.62% the S&P500.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.28 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It has a 30.38 P/E ratio. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

More notable recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: which released: “A Preview Of Halozyme Therapeutics Q3 Earnings” on November 06, 2018, also with their article: “Halozyme Q3 revenues $25.6M, guidance raised” published on November 06, 2018, published: “Report: Exploring Fundamental Drivers Behind Entergy, BLACKLINE INC, HollyFrontier, Hill-Rom, Apache, and …” on November 08, 2018. More interesting news about Halozyme Therapeutics, Inc. (NASDAQ:HALO) were released by: and their article: “The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos …” published on November 06, 2018 as well as‘s news article titled: “Premarket analyst action – healthcare” with publication date: October 19, 2018.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News